Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents

Cancer statistics, 2014

Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.5K citations · Full text

Epidemiology Of Cancer, Cancer Registration, United States +17

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.

Scott H. Kaufmann, Serge Desnoyers, Yvonne Ottaviano et al. · PubMed · 1993 · 1.9K citations

Chemoprevention Strategy, Basal Padprp Activity, Medicine +13

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 739 citations · Full text

Pi3 Kinase, Chemoprevention Strategy, Pharmacotherapy +18

KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties

Kazuhide Nakamura, Eri Taguchi, Atsushi Yamamoto et al. · Cancer Research · 2006 · 204 citations · Full text